TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 19, No. 21 November 1, 2013
__________________________________________________________
TRIGGER is also available by RSS Feed:
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
UPCOMING MEETINGS & EVENTS
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 19, No. 21 November 1, 2013
(The next issue will be on November 15, 2013)
TRIGGER is also available by RSS Feed:
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
ANNOUNCEMENTS
None Submitted for this issue.
__________________________________________________________
SSC 2014 - Partner Opportunities Available
ISTH is
soliciting partners for the upcoming SSC 2014 meeting in Milwaukee, WI, USA.
Your participation and partnership as a sponsor will
associate your brand with innovation and a commitment to leadership
development, scientific discovery and well-informed standardization in our
field. You can download a Sponsorship
Prospectus at:
*** ***
*** ***
ISTH Reach-the-World Fellowships are available for
scientists in our field who work in developing countries. Application deadline
is January 1, 2014. For more information:
*** ***
*** ***
Kenneth M. Brinkhous Young Investigator Prize in
Thrombosis (Sponsored by the Council on Arteriosclerosis, Thrombosis and Vascular
Biology of the AHA) recognizes outstanding endeavors by new investigators in
fundamental and applied research in Thrombosis.
Applicants must be an AHA member. Persons with doctoral degrees are
eligible for 12 years following receipt of their terminal degree. Applicants
must have a sustained research effort in any area related to thrombosis as
evidenced by a peer-reviewed manuscript in the field. Finalists from previous
years are not eligible. There are no citizenship requirements.
Applicants must submit an abstract describing new,
unpublished work in the field of thrombosis to ATVB 2014. A single manuscript,
either unpublished or accepted for publication after January 1, 2013, is
required as part of the application. The manuscript may be from a project
distinct from the abstract submitted to ATVB 2014. The finalists will present
their research results during a special session at the ATVB 2014 Scientific
Sessions in Toronto, Ontario. How to Apply: The applicant must submit an original abstract to
the ATVB 2014 Scientific Sessions.
(Submission dates are October 15, 2013 through January
24, 2014.) Select the Brinkhous Prize during the abstract submission process.
By January 24, 2014, the following must be submitted by uploading into the
abstract submission system (at the "Awards Application Materials
Upload" step): (a)
A cover letter declaring the application for the Kenneth M. Brinkhous
Young Investigator Prize in Thrombosis. (b) A manuscript that is either
unpublished or accepted for publication after January 1, 2013. © A complete
curriculum vitae, including bibliography, and clear documentation demonstrating
that the applicant received their terminal doctoral degree in the previous 12
years. Applications must be submitted by
January 24, 2014 Questions may be directed to Julie Green, Conference Manager, Julie DOT green AT heart DOT org
__________________________________________________________
PAPERS IN PRESSNone Submitted for this issue.
UPCOMING MEETINGS & EVENTS
General info on upcoming meetings of interest:
http://tf7.org/meetings.htm
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
ISTH also maintains a list of upcoming meetings of
interest:
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":
Agrawal P, Thakur Z, Kulharia M (2013) Homology modeling
and structural validation of tissue factor pathway inhibitor. Bioinformation
9:808-812.
Ben-Hadj-Khalifa S, Lakhal B, Mahjoub T, Almawi WY (2013)
Contribution of coagulation factor VII R353Q, -323P0/10 and HVR4 polymorphisms
to coronary artery disease in Tunisians. J Thromb Thrombolysis 35:243-249.
Bjorkman S (2013) Comparative pharmacokinetics of factor
VIII and recombinant factor IX: for which coagulation factors should half-life
change with age? Haemophilia 19:882-886.
Chang LH, Pan SL, Lai CY, Tsai AC, Teng CM (2013)
Activated PAR-2 regulates pancreatic cancer progression through
ILK/HIF-alpha-induced TGF-alpha expression and MEK/VEGF-A-mediated
angiogenesis. Am J Pathol 183:566-575.
Chen C, Mei H, Shi W, Deng J, Zhang B, Guo T, . . . Hu Y (2013) EGFP-EGF1-conjugated PLGA nanoparticles for
targeted delivery of siRNA into injured brain microvascular endothelial cells
for efficient RNA interference. PLoS One 8:e60860.
Chen D, McVey JH, Dorling A (2013) Enhanced effect of
inhibition of thrombin on endothelium in murine endotoxaemia: Specific
inhibition of thrombocytopenia. Thromb Res.
Cho AH, Khosla R (2013) A case of massive airway clotting
after use of activated factor VII for massive hemoptysis: management with
flexible bronchoscopy and cryoadhesion. J Bronchology Interv Pulmonol
20:276-277.
Chuansumrit A, Sirachainan N, Panuwannakorn M,
Wongwerawattanakoon P, Kadegasem P, Choeyprasert W, Sasanakul W (2013) Safety
and efficacy of recombinant activated factor VII for long-term secondary
prophylaxis in a haemophilia boy with high-titre inhibitors. Haemophilia
19:e182-183.
DeFrates SR, McDonagh KT, Adams VR (2013) The reversal of
inhibitors in congenital hemophilia. Pharmacotherapy 33:157-164.
Dickneite G, Hoffman M (2013) Reversing the new oral
anticoagulants with prothrombin complex concentrates (PCCs): what is the
evidence? Thromb Haemost 111.
Ebo DG, Faber M, Sabato V, Leysen J, Gadisseur A, Bridts
CH, De Clerck LS (2013) Sensitization to the mammalian oligosaccharide
galactose-alpha-1,3-galactose (alpha-gal): experience in a flemish case series. Acta Clin Belg
68:206-209.
Geddings JE, Mackman N (2013) Comment on "Tissue
factor expressed by microparticles is associated with mortality but not with
thrombosis in cancer patients". Thromb Haemost 111.
Gil-Bernabe AM, Lucotti S, Muschel RJ (2013) Coagulation
and metastasis: what does the experimental literature tell us? Br J Haematol
162:433-441.
Girolami A, Berti de Marinis G, Bertozzi I, Peroni E,
Tasinato V, Lombardi AM (2013) Discrepant ratios of arterial vs. venous
thrombosis in hemophilias A and B as compared to FVII deficiency. Eur J
Haematol 91:152-156.
Hernandez C, Roncal C, Orbe J, Paramo JA (2013) Tissue
factor expressed by microparticles is associated with mortality but not with
thrombosis in cancer patients. Reply to a comment by Geddings and Mackman.
Thromb Haemost 111.
Higgins P, Brown SA (2013) Pulmonary embolus in a
haemophilia patient. J Paediatr Child Health 49:423.
Hilhorst M, Winckers K, Wilde B, van Oerle R, Ten Cate H,
Cohen Tervaert JW (2013) Patients with Antineutrophil Cytoplasmic Antibodies
Associated Vasculitis in Remission Are Hypercoagulable. J Rheumatol.
Hyseni A, Kemperman H, de Lange DW, de Groot PG, Linssen
M, Kesecioglu J, . . . Roest M (2013) Increased mortality in systemic
inflammatory response syndrome patients with high levels of coagulation factor
VIIa. J Thromb Haemost.
Jesel L, Arentz T, Herrera C, Trenk D, Zobairi F, Abbas
M, . . . Morel O (2013) Do Atrial differences in Endothelial Damage, Leukocyte
and Platelet Activation, or Tissue Factor Activity Contribute to
Chamber-Specific Thrombogenic Status in Patients with Atrial Fibrillation? J
Cardiovasc Electrophysiol.
Kim TO, Park J, Kang MJ, Lee SH, Jee SR, Ryu DY, . . . Yi
JM (2013) DNA hypermethylation of a selective gene panel as a risk marker for
colon cancer in patients with ulcerative colitis. Int J Mol Med 31:1255-1261.
Knol HM, Mulder AB, Bogchelman DH, Kluin-Nelemans HC, van
der Zee AG, Meijer K (2013) The prevalence of underlying bleeding disorders in
patients with heavy menstrual bleeding with and without gynecologic
abnormalities. Am J Obstet Gynecol 209:202 e201-207.
Kocaturk B, Van den Berg YW, Tieken C, Mieog JS, de
Kruijf EM, Engels CC, . . . Versteeg HH (2013) Alternatively spliced tissue
factor promotes breast cancer growth in a beta1 integrin-dependent manner. Proc
Natl Acad Sci U S A 110:11517-11522.
Lavrentieva A (2013) Replacement of specific coagulation
factors in patients with burn: a review. Burns 39:543-548.
Liang WL, Wei HY, Lin FQ, Zhou JL (2012) [Molecular
analysis of two pedigrees with inherited coagulation factor VII deficiency].
Zhonghua Er Ke Za Zhi 50:817-820.
Ma D, Mizurini DM, Assumpcao TC, Li Y, Qi Y, Kotsyfakis
M, . . . Francischetti IM (2013) Desmolaris, a novel Factor XIa anticoagulant
from the salivary gland of the vampire bat (Desmodus
rotundus) inhibits inflammation and thrombosis in vivo.
Blood.
Persigehl T, Ring J, Bremer C, Heindel W, Holtmeier R,
Stypmann J, . . . Schwoppe C (2013) Non-invasive monitoring of tumor-vessel
infarction by retargeted truncated tissue factor tTF-NGR using multi-modal
imaging. Angiogenesis.
Ratanapo S, Ungprasert P, Srivali N, Cheungpasitporn W, Bischof EF (2013) Reversal of a
dabigatran overdose: what are possible options? Am J Med Sci 346:259.
Rech TH, Crispim D, Rheinheimer J, Barkan SS, Osvaldt AB,
Grezzana Filho TJ, . . . Leitao CB
(2013) Brain Death-Induced Inflammatory Activity in Human
Pancreatic Tissue: A Case-Control Study. Transplantation.
Rujirojindakul P, Rujirojindakul P, McNeil EB, Geater AF,
Chanchayanon T, Sangthong B, Chittithavorn V (2013) Prediction score for
effective bleeding control using recombinant activated factor VII in
perioperative nonhemophilic patients. Am J Surg 206:326-332.
Salcioglu Z, Tugcu D, Akcay A, Sen HS, Aydogan G, Akici
F, . . . Baslar Z (2013) Surgical interventions in childhood rare factor deficiencies: a single-center experience from Turkey.
Blood Coagul Fibrinolysis.
Sevy AM, Healey JF, Deng W, Spiegel PC, Meeks SL, Li R
(2013) Epitope mapping of inhibitory antibodies targeting the C2 domain of
coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry. J
Thromb Haemost.
Shrestha C, Ito T, Kawahara K, Shrestha B, Yamakuchi M,
Hashiguchi T, Maruyama I (2013) Saturated fatty acid palmitate induces
extracellular release of histone H3: a possible mechanistic basis for high-fat
diet-induced inflammation and thrombosis. Biochem Biophys Res Commun
437:573-578.
Soff GA (2013) Commentary on "Microparticle-associated tissue factor activity in
patients with metastatic pancreatic cancer and its effect on fibrin clot
formation". Transl Res.
Stewart WS, Pettit H (2013) Experiences with an activated
4-factor prothrombin complex concentrate (FEIBA) for reversal of
warfarin-related bleeding. Am J Emerg Med 31:1251-1254.
Sun L, Liu Y, Lin S, Shang J, Liu J, Li J, . . .Zhang L (2013) Early growth response gene-1 and
hypoxia-inducible factor-1alpha affect tumor metastasis via regulation of
tissue factor. Acta Oncol 52:842-851.
Tseng JC, Chang LC, Jiang BY, Liu YC, Chen HJ, Yu CT, Hua
CC (2013) Elevated circulating levels of tissue factor-positive microvesicles
are associated with distant metastasis in lung cancer. J Cancer Res Clin Oncol.
Uszynski W, Zekanowska E, Uszynski M, Zylinski A,
Kuczynski J (2013) New observations on procoagulant properties of amniotic
fluid: Microparticles (MPs) and tissue factor-bearing MPs
(MPs-TF), comparison with maternal blood plasma. Thromb Res.
Valentino LA, Allen G, Gill JC, Hurlet A, Konkle BA,
Leissinger CA, . . . Stine K (2013) Case studies in the management of
refractory bleeding in patients with haemophilia A and inhibitors. Haemophilia
19:e151-166.
Wang HX, Li XM, Han XH, Jiang YJ, Zhu GH, Zhuang WC
(2011) [Clinical significance of tissue factor and vascular endothelial growth
factor expressions on CD14+ monocytes in patients with non Hodgkin lymphoma].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao 33:427-431.
Zantek ND, Hsu P, Refaai MA, Ledford-Kraemer M, Meijer P,
Van Cott EM (2013) Factor VII assay
performance: an analysis of the North American
Specialized Coagulation Laboratory Association proficiency testing results. Int
J Lab Hematol 35:314-321.
Zhang Q, Liu X, Li C, Liao D, Ouyang Z, Zheng J, Song X
(2013) Tissue factor-targeted lidamycin inhibits growth and metastasis of colon
carcinoma. Oncol Lett 6:801-806.
Zhang Y, Wang L, Zhou W, Wang H, Zhang J, Deng S, . . .
Ma D (2013) Tissue factor pathway
inhibitor-2: a novel gene involved in zebrafish central
nervous system development. Dev Biol 381:38-49.
Zheng Y, Song WP, Zhao YY, Yang CQ (2013) [Lung
expression of tissue factor mRNA and its significance in a rat model of
hepatopulmonary syndrome]. Zhonghua Gan Zang Bing Za Zhi 21:701-704.
Zhou H, Sheng L, Wang H, Xie H, Mu Y, Wang T, Yan J
(2013) Anti-betaGPI/betaGPI stimulates activation of THP-1 cells through
TLR4/MD-2/MyD88 and NF-kappaB signaling pathways. Thromb Res.
http://www.ncbi.nlm.nih.gov/pubmed/24157085
__________________________________________________________
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.
DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________
No comments:
Post a Comment